Gates Foundation Pushes OA

The organization is mandating open access to publications resulting from research it funds.

Written byTracy Vence
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

FLICKR, DUNCAN HULLAs of January 1, the Bill & Melinda Gates Foundation is adopting an open-access (OA) policy, which will enable “unrestricted access and reuse of all peer-reviewed published research funded, in whole or in part, by the foundation, including any underlying data sets,” the organization announced last week (November 20). The Gates Foundation added that it will allow journal publishers to apply embargoes of up to 12-months on accessibility to and publication of data sets, although only through January 2017.

As the Nature News blog noted: “If strictly enforced, it would prevent Gates-funded researchers from publishing in well-known journals such as Nature and Science.”

Under the terms of its OA policy, the Gates Foundation will require that publications resulting from research it funds be immediately made accessible online (under a Creative Commons Attribution 4.0 Generic or an equivalent license). The organization said it will “pay reasonable fees required by a publisher to effect publication on these terms.”

Peter Suber, director of the Office for Scholarly Communication at Harvard University, told Nature that the policy enforcement “would be major if publishers that didn’t previously use CC-BY start to use it, even for the subset of authors funded by the Gates Foundation” or if “publishers that didn’t ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies